Drug intelligence / Profile preview

AX-013

Development stage: Preclinical
Lead developer: Axiom Biosciences
Modality: Cell Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies

Overview

AX-013 is an AI-designed, *in vivo* chimeric antigen receptor (CAR) T-cell therapy being developed by Axiom Biosciences for the treatment of autoimmune diseases. Utilizing Axiom's computational design platform, AX-013 is engineered to facilitate the genetic modification of T cells directly within the patient's body, aiming to eliminate pathogenic cell populations without the need for the complex *ex vivo* cell processing associated with traditional CAR-T therapies. The program is currently in the preclinical stage of development.

Beyond the preview

Go deeper on AX-013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AX-013.

Explore the full profile